Abstract Interleukin-2 (IL-2) and its receptor (IL-2R) are essential in orchestrating immune
responses. Their function and expression in the tumor microenvironment make them …

Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple
myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell …

The majority of cancer patients receive radiotherapy during the course of treatment,
delivered with curative intent for local tumor control or as part of a multimodality regimen …

CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory
hematological malignancies, but responses in solid tumors have been limited so far. One of …

Bispecific T cell engagers (bsTCEs) have emerged as a promising class of cancer
immunotherapy. Several bsTCEs have achieved marketing approval; dozens more are …

Elranatamab (elranatamab-bcmm; ELREXFIO™) is a bispecific B-cell maturation antigen
(BCMA)-directed CD3 T cell engager being developed by Pfizer for the treatment of multiple …

Antibody engineering has developed into a wide-reaching field, impacting a multitude of
industries, most notably healthcare and diagnostics. The seminal work on developing the …

Antibody-based therapeutics constitute a rapidly growing class of pharmaceutical
compounds. However, monoclonal antibodies, which specifically engage only one target …

Bispecific antibodies (BsAbs) are a new group of targeted therapies that are revolutionizing
the treatment landscape of B-cell non-Hodgkin's lymphoma (B-NHL). In the …

In recent years, to treat a diverse array of cancer forms, considerable advancements have
been achieved in the field of cancer immunotherapies. However, these therapies encounter …